Control of asthma by omalizumab: the role of CD4+Foxp3+ regulatory T cells

• Published in: Clinical and experimental allergy Vol. 46; no. 12; pp. 1614 - 1616
• Main Authors: Amat, F., Tallon, P., Foray, A. P., Michaud, B., Lambert, N., Saint-Pierre, P., Chatenoud, L., Just, J.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.12.2016; Wiley Subscription Services, Inc; Wiley
• Subjects: Anti-Asthmatic Agents - therapeutic use; Asthma - drug therapy; Asthma - immunology; CD4 Antigens; Child; Cross-Sectional Studies; Eosinophilia - drug therapy; Female; Flow Cytometry; Forkhead Transcription Factors - immunology; Human health and pathology; Humans; Interleukin-2 Receptor alpha Subunit; Life Sciences; Male; Omalizumab - therapeutic use; Prospective Studies; T-Lymphocytes, Regulatory - cytology; T-Lymphocytes, Regulatory - immunology
• ISSN: 0954-7894; 1365-2222
• DOI: 10.1111/cea.12839

Allergic asthma is an inflammatory disease of the airways, resulting from an inappropriate immune response to inhaled allergens, which involves multiple inflammatory cells and mediators that contribute to airway hyper-responsiveness. Omalizumab is a monoclonal antibody, specifically directed to the C-Epsilon3 domain of immunoglobulin E (IgE), indicated as an additional therapy in severe allergic asthma [1]. Impaired function of regulatory T cells (Treg) is incriminated in the aberrant asthma inflammatory response [2].